References
- URL:http://www.alsuntangled.com/open.php. Accessed: 2016-03-03. (Archived by WebCite® at http://www.webcitation.org/6fjoKNLjB)
- Yu J, Zhu H, Ko D, Kindy M. Motorneuronotrophic factor analog GM6 reduces infarct volume and behavioral deficits following transient ischemia in the mouse. Brain Res. 2008;1238:143–53.
- URL:http://www.genervon.com/genervon/science_development.php. Accessed: 2016-03-03. (Archived by WebCite® at http://www.webcitation.org/6fjobLxFz)
- Emails from ALSUntangled to [email protected], and [email protected] 12/15/15and 12/21/15. and telephone call from ALSUntangled to Dorothy Ko at Genervon, 12/21/15.
- Other emails from clinicians who are ALSUntangled members to [email protected], or [email protected].
- URL:http://www.genervon.com/genervon/about_leadership.php. Accessed: 2016-03-03. (Archived by WebCite® at http://www.webcitation.org/6fjojUho3).
- Sorenson EJ, Windebank AJ, Mandrekar JN, Bamlet WR, Appel SH, Armon C, et al. Subcutaneous IGF-1 is not beneficial in two-year ALS trial. Neurology. 2008;71:1770–5.
- ALS CNTF Treatment Study Group. A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rhCNTF) in amyotrophic lateral sclerosis. Neurology. 1996;46:1249–55.
- Kalra S, Genge A, Arnold DL. A prospective, randomized, placebo-controlled evaluation of corticoneuronal response to intrathecal BDNF therapy in ALS using magnetic resonance spectroscopy: feasibility and results. Amyotroph Lateral Scler Other Motor Neuron Disord. 2003;4:22–6.
- Ludolph A, Bendotti C, Blaugrund E, Chio A, Greensmith L, Loeffler J, et al . Guidelines for preclinical animal research in ALS/MND: a consensus meeting. Amyotroph Lateral Scler. 2010;11:38–45.
- Benatar M. Lost in translation: treatment trials in the SOD1 mouse and in human ALS. Neurobiol Dis. 2007;26:1–13.
- URL:http://www.genervon.com/genervon/images/data2015062902.pdf. Accessed: 2016-03-03. (Archived by WebCite® at http://www.webcitation.org/6fjprylxt)
- URL:http://www.genervon.com/genervon/PR20151210.php. Accessed: 2016-03-03. (Archived by WebCite® at http://www.webcitation.org/6fjpzEcqO)
- Mateen F, Sorenson E, Daube J. Strength, physical activity and fasciculations in patients with ALS. Amyotroph Lateral Scler. 2008;9:120–1.
- Bedlack RS, Vaughan T, Wicks P, Heywood J, Sinani E, Selsov R, et al. How common are ALS plateaus and reversals? Neurology. 2016;86:808–12.
- Emails between ALSUntangled and various patients and families fighting ALS.
- URL:https://clinicaltrials.gov/ct2/show/NCT01854294?term=gm604&rank =1. Accessed: 2016-03-03. (Archived by WebCite® at http://www.webcitation.org/6fjq4NvEe)
- URL:http://www.genervon.com/genervon/PR20140429.php. Accessed: 2016-03-03. (Archived by WebCite® at http://www.webcitation.org/6fjq9RaOY)
- URL:http://www.genervon.com/genervon/images/data2015062903.pdf. Accessed: 2016-03-03. (Archived by WebCite® at http://www.webcitation.org/6fjqEZ9h2)
- URL:http://www.genervon.com/genervon/medicines_2015062904.php. Accessed: 2016-03-03. (Archived by WebCite® at http://www.webcitation.org/6fjqKuVq4)
- URL:http://www.genervon.com/genervon/images/data2015062902.pdf . Accessed: 2016-03-03. (Archived by WebCite® at http://www.webcitation.org/6fjqjdVGx)
- Donofrio P, Bedlack R. Historical controls in ALS trials. A high seas rescue? Neurology. 2011;77:936–7.
- URL:https://clinicaltrials.gov/ct2/show/NCT00349622?term=ceftriaxone+als&rank=1. Accessed: 2016-03-03. (Archived by WebCite® at http://www.webcitation.org/6fjqts4yh)
- Pagononi S, Deng J, Jaffa M, Cudkowicz M, Willis A. Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis. Muscle Nerve. 2011;44:20–4.
- URL:http://www.translateals.com/?p=16. Accessed: 2016-03-03. (Archived by WebCite® at http://www.webcitation.org/6fjqy77YF)
- URL:http://www.genervon.com/genervon/PR20150420.php. Accessed: 2016-03-03. (Archived by WebCite® at http://www.webcitation.org/6fjr510w5)
- Atassi N, Berry J, Shui A, Zach N, Sherman A, Sinani E, et al. The Pro-act database. Design, initial analyses and predictive features. Neurology. 2014;83:1719–25.
- Chio A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E, et al., Eurals Cosnortium. Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler. 2009;10:310–23.
- Button K, Ioannidis J, Mokrysz C, Nosek B, Flint J, Robinson E, et al. Power failure: why small sample size undermines the reliability of neuroscience. Nature Rev Neurosci. 2013;14:365–76.
- Ioannidis J. Why most published research findings are false. PLoS Med. 2005;2:e124.
- Fornai F, Longone P, Cafaro L, Kastsiuchenka O, Ferruci M, Manca M, et al. Lithium delays progression of amyotrophic lateral sclerosis. PNAS. 2008;105:2052–7.
- Cudkowicz M, Bozik M, Ingersoll E, Miller R, Mitsumoto H, Shefner J, et al. The effects of dexpramipexole in individuals with amyotrophic lateral sclerosis. Nat Med. 2011;17:1652–6.
- URL:http://www.genervon.com/genervon/images/data20150131.pdf. Accessed: 2016-03-03. (Archived by WebCite® at http://www.webcitation.org/6fjrAoGwz)
- URL:http://www.genervon.com/genervon/images/data2015062902.pdf. Accessed: 2016-03-03. (Archived by WebCite® at http://www.webcitation.org/6fjrFnPlV)
- Miller R, Munsat T, Swash M, Brooks B. Consensus guidelines for the design and implementation of clinical trials in ALS. J Neurol Sci. 1999;169:2–12.
- Berry R. Validity and ethics in science. Science. 2003;300:1341.
- Smith R. Peer review: a flawed process at the heart of science and journals. J R Soc Med. 2006;99:178–82.
- URL:http://www.fda.gov/Drugs/DrugSafety/ucm443242.htm. Accessed: 2016-03-03. (Archived by WebCite® at http://www.webcitation.org/6fjrTXe2i)
- URL:http://www.fda.gov/NewsEvents/PublicHealthFocus/ExpandedAccessCompassionateUse/default.htm. Accessed: 2016-03-03. (Archived by WebCite® at http://www.webcitation.org/6fjrkD6Sq)